PharmaBlock Sciences (Nanjing) Past Earnings Performance
Past criteria checks 1/6
PharmaBlock Sciences (Nanjing) has been growing earnings at an average annual rate of 6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 20.7% per year. PharmaBlock Sciences (Nanjing)'s return on equity is 6.4%, and it has net margins of 11.2%.
Key information
6.0%
Earnings growth rate
4.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 20.7% |
| Return on equity | 6.4% |
| Net Margin | 11.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Taking Some Risk With Its Debt
Jul 31
PharmaBlock Sciences (Nanjing) (SZSE:300725) Is Increasing Its Dividend To CN¥0.31
Jun 12PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Apr 21PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) Looks Just Right With A 25% Price Jump
Mar 07Revenue & Expenses Breakdown
How PharmaBlock Sciences (Nanjing) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1,626 | 182 | 259 | 140 |
| 31 Mar 24 | 1,719 | 189 | 259 | 155 |
| 31 Dec 23 | 1,725 | 197 | 263 | 169 |
| 30 Sep 23 | 1,701 | 219 | 265 | 180 |
| 30 Jun 23 | 1,704 | 275 | 269 | 189 |
| 31 Mar 23 | 1,642 | 301 | 268 | 189 |
| 01 Jan 23 | 1,595 | 314 | 256 | 168 |
| 30 Sep 22 | 1,483 | 294 | 240 | 154 |
| 30 Jun 22 | 1,315 | 258 | 211 | 135 |
| 31 Mar 22 | 1,251 | 488 | 184 | 112 |
| 31 Dec 21 | 1,202 | 487 | 177 | 114 |
| 30 Sep 21 | 1,200 | 484 | 171 | 115 |
| 30 Jun 21 | 1,184 | 478 | 161 | 103 |
| 31 Mar 21 | 1,137 | 226 | 167 | 103 |
| 31 Dec 20 | 1,022 | 184 | 157 | 91 |
| 30 Sep 20 | 923 | 177 | 144 | 77 |
| 30 Jun 20 | 831 | 170 | 130 | 78 |
| 31 Mar 20 | 681 | 147 | 111 | 72 |
| 31 Dec 19 | 662 | 152 | 100 | 69 |
| 30 Sep 19 | 603 | 157 | 87 | 66 |
| 30 Jun 19 | 558 | 149 | 87 | 56 |
| 31 Mar 19 | 531 | 147 | 79 | 50 |
| 31 Dec 18 | 478 | 133 | 79 | 44 |
| 30 Sep 18 | 417 | 109 | 75 | 37 |
| 30 Jun 18 | 362 | 89 | 61 | 43 |
| 31 Mar 18 | 319 | 75 | 65 | 34 |
| 31 Dec 17 | 273 | 67 | 62 | 25 |
| 30 Sep 17 | 244 | 62 | 66 | 17 |
| 30 Jun 17 | 219 | 44 | 88 | 0 |
| 31 Mar 17 | 196 | 37 | 85 | 0 |
| 31 Dec 16 | 188 | 36 | 82 | 0 |
| 30 Sep 16 | 183 | 30 | 81 | 0 |
| 30 Jun 16 | 177 | 31 | 54 | 0 |
| 31 Mar 16 | 156 | 25 | 47 | 0 |
| 31 Dec 15 | 136 | 20 | 59 | 0 |
| 31 Dec 14 | 77 | 22 | 25 | 0 |
| 31 Dec 13 | 59 | 18 | 19 | 0 |
Quality Earnings: 300725 has a large one-off gain of CN¥49.8M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 300725's current net profit margins (11.2%) are lower than last year (16.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300725's earnings have grown by 6% per year over the past 5 years.
Accelerating Growth: 300725's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300725 had negative earnings growth (-33.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Return on Equity
High ROE: 300725's Return on Equity (6.4%) is considered low.